ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
2
Goldsmith CS, Elliot LH, Peters CJ, Zaki SR, 1995. Ultrastruc-tural characteristics of Sin Nombre virus, causative agent of hantavirus pulmonary syndrome. Arch Virol 140 :2107–2122.
-
3
Pinheiro FP, Travassos da Rosa APA, Vasconcelos PFC, 2004. Oropouche fever. Feigin RD, ed. Textbook of Pediatric Infectious Diseases. Philadelphia: WB Saunders Co., 2418–2423.
-
4
LeDuc JW, Pinheiro FP, 1988. Oropouche fever. Monath TP, ed. The Arboviruses: Epidemiology and Ecology. Volume IV. Boca Raton, FL: CRC Press, 1–15.
-
5
Brinton MA, Gavin EI, Lo WK, Pinto AJ, Morahan PS, 1993. Characterization of murine Caraparu Bunyavirus liver infection and immunomodulator-mediated antiviral protection. Antiviral Res 20 :155–171.
-
6
Jonkers AH, Spence L, Olivier O, 1968. Laboratory studies with rodents and native to Trinidad. Am J Trop Med Hyg 17 :299–307.
-
7
March RW, Hetrick FM, 1967. Studies on Guaroa virus. Am J Trop Med Hyg 16 :191–195.
-
8
Travassos da Rosa APA, Travassos da Rosa JFS, Pinheiro FP, Vasconcelos PFC, 1997. Doenças Infecciosas e Parasitárias: Enfoque Amazônico. Leão RNQ, ed. Belém: CEJUP, 207–241.
-
9
De Clercq E, 1993. Antiviral agents: characteristic activity spectrum depending on the molecular target with which they interact. Adv Virus Res 42 :1–55.
-
10
Crotty S, Cameron CE, Andini R, 2001. RNA virus error catastrophe: direct molecular test by using Ribavirin. Proc Natl Acad Sci USA 98 :6895–6900.
-
11
Hruska JF, Bernstein JM, Douglas RG Jr, Hall CB, 1980. Effects of ribavirin on respiratory syncytial virus in vitro.Antimicrob Agents Chemother 17 :770–775.
-
12
Leyssen P, Balzarini J, De Clercq E, Neyts J, 2005. The predominant mechanism by which ribavirin exerts its antiviral activity in vitro against flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehydrogenase. J Virol 79 :1943–1947.
-
13
Neyts J, Meerbach A, McKenna P, De Clercq E, 1996. Use of the yellow fever virus vaccine strain 17D for the study of strategies for the treatment of yellow fever virus infections. Antiviral Res 30 :125–132.
-
14
Jordan I, Briese T, Fischer N, Lau JY, Lipkin WI, 2000. Ribavirin inhibits West Nile virus replication and cytopathic effect in neural cells. J Infect Dis 82 :1214–1217.
-
15
Crotty S, Maag D, Arnold JJ, Zhong W, Lau JY, Hong Z, Andino R, Cameron CE, 2000. The broad-spectrum antiviral ribo-nucleoside ribavirin is an RNA virus mutagen. Nat Med 6 :1375–1379.
-
16
Durr FE, Lindh HF, 1975. Efficacy of ribavirin against influenza virus in tissue culture and in mice. Ann NY Acad Sci 255 :366–371.
-
17
Jahrling PB, Hesse RA, Eddy GA, Johnson KM, Callis RT, Stephen EL, 1980. Lassa virus infection of rhesus monkeys: pathogenesis and treatment with ribavirin. J Infect Dis 141 :580–589.
-
18
Andrei G, De Clercq E, 1990. Inhibitory effect of selected antiviral compounds on arenavirus replication in vitro.Antiviral Res 14 :287–299.
-
19
Sidwell RW, Huffman JH, Barnett BB, Pifat DY, 1988. In vitro and in vivo Phlebovirus inhibition by ribavirin. Antimicrob Agents Chemother 32 :331–336.
-
20
Cassidy LF, Patterson JL, 1989. Mechanism of La Crosse virus inhibition by ribavirin. Antimicrob Agents Chemother 33 :2009–2011.
-
21
Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, Shiffman ML, Zeuzem S, Craxi A, Ling MH, Albrecht J, 1998. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 339 :1493–1499.
-
22
McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK, 1998. Interferon alfa-2b alone or in combination with rib-avirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 339 :1485–1492.
-
23
Wyde PR, 1998. Respiratory syncytial virus (RSV) disease and prospects for its control. Antiviral Res 39 :63–79.
-
24
McCormick JB, King IJ, Webb PA, Scribner CL, Craven RB, Johnson KM, Elliott LH, Belmont-Williams R, 1986. Lassa fever. Effective therapy with ribavirin. N Engl J Med 314 :20–26.
-
25
Graci JD, Cameron CE, 2006. Mechanisms of action of ribavirin against distinct viruses. Rev Med Virol 16 :37–48.
-
26
Streeter DG, Witkowski JT, Khare GP, Sidwell RW, Bauer RJ, Robins RK, Simon LN, 1973. Mechanism of action of 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (Virazole), a new broad-spectrum antiviral agent. Proc Natl Acad Sci USA 70 :1174–1178.
-
27
Goswami BB, Borek E, Shalma DK, Fujitaki J, Smith RA, 1979. The broad spectrum antiviral agent ribavirin inhibits capping of mRNA. Biochem. Biophys. Res. Commun. 89 :830–836.
-
28
Eriksson B, Helgstrand E, Johannson N, Larsson A, Misionny A, Noren JO, Philipson L, Stenberg K, Stening G, Stridh S, Oberg B, 1977. Inhibition of influenza virus ribonucleic acid polymer-ase by ribavirin triphosphate. Antimicrob Agents Chemother 11 :946–951.
-
29
Ning Q, Brown D, Parodo J, Cattral M, Gorczynski R, Cole E, Fung L, Ding JW, Liu MF, Rotstein O, Phillips MJ, Levy G, 1998. Ribavirin inhibits viral-induced macrophage production of TNF, IL-1, the procoagulant fgl2 prothrombinase, and preserves TH1 cytokine production but inhibits TH2 cytokine response. J Immunol 160 :3487–3493.
-
30
Scheidel LM, Durbin RK, Stollar V, 1987. Sindbis virus mutants resistant to mycophenolic acid and ribavirin. Virology 158 :1–7.
-
31
Morens DM, Halstead SB, Repik PM, Putvatana R, Raybourne N, 1985. Simplified plaque reduction neutralization assay for dengue viruses by semimicro methods in BHK-21 cells: comparison of the BHK suspension test with standard plaque reduction neutralization. J Clin Microbiol 22 :250–254.
-
32
Diamond MS, Zachariah M, Harris E, 2002. Mycophenolic Acid inhibits Dengue virus infection by preventing replication of viral RNA. Virology 304 :211–221.
-
33
Lipsky JJ, 1996. Mycophenolate mofetil. Lancet 348 :1357–1359.
-
34
Scheidel LM, Stollar V, 1991. Mutations that confer resistance to mycophenolic acid and ribavirin on Sindbis virus map to the nonstructural protein nsP1. Virology 181 :490–499.
-
35
Jin H, Elliot RM, 1993. Non-viral sequences at the 5′ends of Dugbe nairovirus S mRNAs. J Gen Virol 74 :2293–2297.
-
36
Tan ELC, Ooi EE, Lin C, Tan HC, Ling AE, Lim B, Stanton LW, 2004. Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs. Emerg. Infect. Dis. 10 :581–586.
-
37
Young KC, Lindsay KL, Lee KJ, Liu WC, He JW, Milstein SL, Lai MM, 2003. Identification of a ribavirin-resistant NS5B mutation of hepatitis C virus during ribavirin monotherapy. Hep-atology 38 :869–878.
-
38
Pfeiffer JK, Kirkegaard K, 2003. A single mutation in poliovirus RNA-dependent RNA polymerase confers resistance to mutagenic nucleotide analogs via increased fidelity. Proc Natl Acad Sci USA 100 :7289–7294.
-
39
Arnold JJ, Vignuzzi M, Stone JK, Andini R, Cameron CE, 2005. Remote site control of an active site fidelity checkpoint in a viral RNA-dependent RNA polymerase. J Biol Chem 280 :25706–25716.
-
40
Allen LB, 1980. Review of in vivo efficacy of ribavirin. Smith RA, Kirkpatrick W, eds. Ribavirin: A Broad Spectrum Antiviral Agent. New York: Academic Press, Inc., 43–58.
-
41
Koff WC, Pratt RD, Elm JL Jr, Venkateshan CN, Halstead SB, 1983. Treatment of intracranial dengue virus infections in mice with a lipophilic derivative of ribavirin. Antimicrob Agents Chemother 24 :134–136.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 330 | 248 | 16 |
| Full Text Views | 315 | 12 | 4 |
| PDF Downloads | 103 | 18 | 4 |
IN VITRO AND IN VIVO STUDIES OF RIBAVIRIN ACTION ON BRAZILIAN ORTHOBUNYAVIRUS
MÁRCIA C. LIVONESI
MÁRCIA C. LIVONESI
Center for Research in Virology, School of Medicine of Ribeirão Preto, University of São Paulo USP, Ribeirão Preto, SP, Brazil
Search for other papers by MÁRCIA C. LIVONESI in
Current site
Google Scholar
PubMed
Search for other papers by MÁRCIA C. LIVONESI in
Current site
Google Scholar
PubMed
RICARDO L. MORO DE SOUSA
RICARDO L. MORO DE SOUSA
Center for Research in Virology, School of Medicine of Ribeirão Preto, University of São Paulo USP, Ribeirão Preto, SP, Brazil
Search for other papers by RICARDO L. MORO DE SOUSA in
Current site
Google Scholar
PubMed
Search for other papers by RICARDO L. MORO DE SOUSA in
Current site
Google Scholar
PubMed
SORAYA J. BADRA
SORAYA J. BADRA
Center for Research in Virology, School of Medicine of Ribeirão Preto, University of São Paulo USP, Ribeirão Preto, SP, Brazil
Search for other papers by SORAYA J. BADRA in
Current site
Google Scholar
PubMed
Search for other papers by SORAYA J. BADRA in
Current site
Google Scholar
PubMed
LUIZ T.M. FIGUEIREDO
LUIZ T.M. FIGUEIREDO
Center for Research in Virology, School of Medicine of Ribeirão Preto, University of São Paulo USP, Ribeirão Preto, SP, Brazil
Search for other papers by LUIZ T.M. FIGUEIREDO in
Current site
Google Scholar
PubMed
Search for other papers by LUIZ T.M. FIGUEIREDO in
Current site
Google Scholar
PubMed
Oropouche, Caraparu, Guama, Guaroa, and Tacaiuma are viruses (genus Orthobunyavirus) that cause human febrile illnesses and encephalitis. The goal of this study was to evaluate the antiviral action of ribavirin on these orthobunyaviruses to achieve a therapeutical agent to treat the diseases caused by these viruses. In vitro results showed that ribavirin (50 μg/mL) had antiviral activity only on the Tacaiuma virus. Addition of guanosine in the culture reversed the antiviral effect of ribavirin on Tacaiuma virus, suggesting that ribavirin inhibited this virus by reducing the intra-cellular guanosine pool. Moreover, ribavirin was not an effective drug in vivo because it was unable to inhibit the death of the mice or virus replication in the brain. The results suggest that ribavirin has no antiviral activity on the Oropouche, Caraparu, Guama, Guaroa, or Tacaiuma viruses; consequently, ribavirin would not be a good therapeutical agent to treat these arboviruses.
Author Notes
ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
2
Goldsmith CS, Elliot LH, Peters CJ, Zaki SR, 1995. Ultrastruc-tural characteristics of Sin Nombre virus, causative agent of hantavirus pulmonary syndrome. Arch Virol 140 :2107–2122.
-
3
Pinheiro FP, Travassos da Rosa APA, Vasconcelos PFC, 2004. Oropouche fever. Feigin RD, ed. Textbook of Pediatric Infectious Diseases. Philadelphia: WB Saunders Co., 2418–2423.
-
4
LeDuc JW, Pinheiro FP, 1988. Oropouche fever. Monath TP, ed. The Arboviruses: Epidemiology and Ecology. Volume IV. Boca Raton, FL: CRC Press, 1–15.
-
5
Brinton MA, Gavin EI, Lo WK, Pinto AJ, Morahan PS, 1993. Characterization of murine Caraparu Bunyavirus liver infection and immunomodulator-mediated antiviral protection. Antiviral Res 20 :155–171.
-
6
Jonkers AH, Spence L, Olivier O, 1968. Laboratory studies with rodents and native to Trinidad. Am J Trop Med Hyg 17 :299–307.
-
7
March RW, Hetrick FM, 1967. Studies on Guaroa virus. Am J Trop Med Hyg 16 :191–195.
-
8
Travassos da Rosa APA, Travassos da Rosa JFS, Pinheiro FP, Vasconcelos PFC, 1997. Doenças Infecciosas e Parasitárias: Enfoque Amazônico. Leão RNQ, ed. Belém: CEJUP, 207–241.
-
9
De Clercq E, 1993. Antiviral agents: characteristic activity spectrum depending on the molecular target with which they interact. Adv Virus Res 42 :1–55.
-
10
Crotty S, Cameron CE, Andini R, 2001. RNA virus error catastrophe: direct molecular test by using Ribavirin. Proc Natl Acad Sci USA 98 :6895–6900.
-
11
Hruska JF, Bernstein JM, Douglas RG Jr, Hall CB, 1980. Effects of ribavirin on respiratory syncytial virus in vitro.Antimicrob Agents Chemother 17 :770–775.
-
12
Leyssen P, Balzarini J, De Clercq E, Neyts J, 2005. The predominant mechanism by which ribavirin exerts its antiviral activity in vitro against flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehydrogenase. J Virol 79 :1943–1947.
-
13
Neyts J, Meerbach A, McKenna P, De Clercq E, 1996. Use of the yellow fever virus vaccine strain 17D for the study of strategies for the treatment of yellow fever virus infections. Antiviral Res 30 :125–132.
-
14
Jordan I, Briese T, Fischer N, Lau JY, Lipkin WI, 2000. Ribavirin inhibits West Nile virus replication and cytopathic effect in neural cells. J Infect Dis 82 :1214–1217.
-
15
Crotty S, Maag D, Arnold JJ, Zhong W, Lau JY, Hong Z, Andino R, Cameron CE, 2000. The broad-spectrum antiviral ribo-nucleoside ribavirin is an RNA virus mutagen. Nat Med 6 :1375–1379.
-
16
Durr FE, Lindh HF, 1975. Efficacy of ribavirin against influenza virus in tissue culture and in mice. Ann NY Acad Sci 255 :366–371.
-
17
Jahrling PB, Hesse RA, Eddy GA, Johnson KM, Callis RT, Stephen EL, 1980. Lassa virus infection of rhesus monkeys: pathogenesis and treatment with ribavirin. J Infect Dis 141 :580–589.
-
18
Andrei G, De Clercq E, 1990. Inhibitory effect of selected antiviral compounds on arenavirus replication in vitro.Antiviral Res 14 :287–299.
-
19
Sidwell RW, Huffman JH, Barnett BB, Pifat DY, 1988. In vitro and in vivo Phlebovirus inhibition by ribavirin. Antimicrob Agents Chemother 32 :331–336.
-
20
Cassidy LF, Patterson JL, 1989. Mechanism of La Crosse virus inhibition by ribavirin. Antimicrob Agents Chemother 33 :2009–2011.
-
21
Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, Shiffman ML, Zeuzem S, Craxi A, Ling MH, Albrecht J, 1998. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 339 :1493–1499.
-
22
McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK, 1998. Interferon alfa-2b alone or in combination with rib-avirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 339 :1485–1492.
-
23
Wyde PR, 1998. Respiratory syncytial virus (RSV) disease and prospects for its control. Antiviral Res 39 :63–79.
-
24
McCormick JB, King IJ, Webb PA, Scribner CL, Craven RB, Johnson KM, Elliott LH, Belmont-Williams R, 1986. Lassa fever. Effective therapy with ribavirin. N Engl J Med 314 :20–26.
-
25
Graci JD, Cameron CE, 2006. Mechanisms of action of ribavirin against distinct viruses. Rev Med Virol 16 :37–48.
-
26
Streeter DG, Witkowski JT, Khare GP, Sidwell RW, Bauer RJ, Robins RK, Simon LN, 1973. Mechanism of action of 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (Virazole), a new broad-spectrum antiviral agent. Proc Natl Acad Sci USA 70 :1174–1178.
-
27
Goswami BB, Borek E, Shalma DK, Fujitaki J, Smith RA, 1979. The broad spectrum antiviral agent ribavirin inhibits capping of mRNA. Biochem. Biophys. Res. Commun. 89 :830–836.
-
28
Eriksson B, Helgstrand E, Johannson N, Larsson A, Misionny A, Noren JO, Philipson L, Stenberg K, Stening G, Stridh S, Oberg B, 1977. Inhibition of influenza virus ribonucleic acid polymer-ase by ribavirin triphosphate. Antimicrob Agents Chemother 11 :946–951.
-
29
Ning Q, Brown D, Parodo J, Cattral M, Gorczynski R, Cole E, Fung L, Ding JW, Liu MF, Rotstein O, Phillips MJ, Levy G, 1998. Ribavirin inhibits viral-induced macrophage production of TNF, IL-1, the procoagulant fgl2 prothrombinase, and preserves TH1 cytokine production but inhibits TH2 cytokine response. J Immunol 160 :3487–3493.
-
30
Scheidel LM, Durbin RK, Stollar V, 1987. Sindbis virus mutants resistant to mycophenolic acid and ribavirin. Virology 158 :1–7.
-
31
Morens DM, Halstead SB, Repik PM, Putvatana R, Raybourne N, 1985. Simplified plaque reduction neutralization assay for dengue viruses by semimicro methods in BHK-21 cells: comparison of the BHK suspension test with standard plaque reduction neutralization. J Clin Microbiol 22 :250–254.
-
32
Diamond MS, Zachariah M, Harris E, 2002. Mycophenolic Acid inhibits Dengue virus infection by preventing replication of viral RNA. Virology 304 :211–221.
-
33
Lipsky JJ, 1996. Mycophenolate mofetil. Lancet 348 :1357–1359.
-
34
Scheidel LM, Stollar V, 1991. Mutations that confer resistance to mycophenolic acid and ribavirin on Sindbis virus map to the nonstructural protein nsP1. Virology 181 :490–499.
-
35
Jin H, Elliot RM, 1993. Non-viral sequences at the 5′ends of Dugbe nairovirus S mRNAs. J Gen Virol 74 :2293–2297.
-
36
Tan ELC, Ooi EE, Lin C, Tan HC, Ling AE, Lim B, Stanton LW, 2004. Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs. Emerg. Infect. Dis. 10 :581–586.
-
37
Young KC, Lindsay KL, Lee KJ, Liu WC, He JW, Milstein SL, Lai MM, 2003. Identification of a ribavirin-resistant NS5B mutation of hepatitis C virus during ribavirin monotherapy. Hep-atology 38 :869–878.
-
38
Pfeiffer JK, Kirkegaard K, 2003. A single mutation in poliovirus RNA-dependent RNA polymerase confers resistance to mutagenic nucleotide analogs via increased fidelity. Proc Natl Acad Sci USA 100 :7289–7294.
-
39
Arnold JJ, Vignuzzi M, Stone JK, Andini R, Cameron CE, 2005. Remote site control of an active site fidelity checkpoint in a viral RNA-dependent RNA polymerase. J Biol Chem 280 :25706–25716.
-
40
Allen LB, 1980. Review of in vivo efficacy of ribavirin. Smith RA, Kirkpatrick W, eds. Ribavirin: A Broad Spectrum Antiviral Agent. New York: Academic Press, Inc., 43–58.
-
41
Koff WC, Pratt RD, Elm JL Jr, Venkateshan CN, Halstead SB, 1983. Treatment of intracranial dengue virus infections in mice with a lipophilic derivative of ribavirin. Antimicrob Agents Chemother 24 :134–136.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 330 | 248 | 16 |
| Full Text Views | 315 | 12 | 4 |
| PDF Downloads | 103 | 18 | 4 |